Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer
SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
SHANGHAI, Jan. 4, 2022 /PRNewswire/ -- Everest Medicines
Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program
SHANGHAI, Dec. 20, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) and Providence Therapeutics ("Providence") announced today that their COVID-19 vaccine, PTX-COVID19-B, has been recommended by an independent advisory group to be part of the WHO Solidarity Trial Vaccines ("STV") clinical t...
Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy
* TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to reduce proteinuria in adults withprimary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g1 * TARPEYO (developed un...
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
SHANGHAI and CALGARY, Canada, Dec. 1, 2021 /PRNewswire/ -- Everest Medicines and Providence Therapeutics ("Providence") jointly announced today that the companies have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant. Scientists from the two com...
Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index
SHANGHAI, Nov. 23, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that th...
Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index
SHANGHAI, Nov. 24, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that th...
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint
SHANGHAI, Nov. 11, 2021 /PRNewswire/ -- Everest Medicines and Gilead Sciences, Inc. (Nasdaq: GILD) jointly announces today that Everest Medicines sponsored (HKEX 1952.HK) Phase2b EVER-132-001 study of sacituzumab govitecan (marketed as Trodelvy® in the United States) met its primary endpoint o...
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program
SHANGHAI, Nov. 8, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that i...
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program
SHANGHAI, Nov. 7, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that i...
Everest Medicines Announces Share Repurchase Transaction Details
SHANGHAI, Nov. 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that it ...
Everest Medicines Initiates Submission of New Drug Application in Hong Kong for XeravaTM for the Treatment of Complicated Intra-abdominal Infections
SHANGHAI, Sept. 29, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206
SHANGHAI, Sept. 24, 2021 /PRNewswire/ -- Everest Medicines
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
VANCOUVER, British Columbia and SHANGHAI, Sept. 23, 2021 /PRNewswire/ --
AbCellera
Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases
SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Enters into Comprehensive Agreements with Providence Therapeutics to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Asia Emerging Markets
SHANGHAI, Sept. 13, 2021 /PRNewswire/ -- Everest Medicines Limited
Everest Medicines Announces Half-Year 2021 Interim Results
SHANGHAI, Aug. 30, 2021 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces Up to HK$100 million Share Repurchase Program
SHANGHAI, Aug. 30, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced t...
Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial Cancer
SHANGHAI, Aug. 26, 2021 /PRNewswire/ -- Everest Medicines
